Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
OPERATING EXPENSES:
Research and development	$ 29,069	$ 19,818	$ 53,970	$ 38,853
General and administrative	14,253	12,846	27,925	25,599
Total operating expenses	43,322	32,664	81,895	64,452
Loss from operations:	(43,322)	(32,664)	(81,895)	(64,452)
OTHER INCOME, NET:
Benefit from R&D tax credit	3,709	2,520	6,810	6,836
Interest income	2,408	638	4,668	1,342
Interest expense	(1,112)	0	(2,210)	0
Foreign exchange gains (losses)	225	1,376	(558)	4,061
Other income (expense), net	167	(11)	295	(6)
Total other income, net	5,397	4,523	9,005	12,233
Loss before income taxes	(37,925)	(28,141)	(72,890)	(52,219)
Income tax expense	(176)	(194)	(398)	(324)
Net loss	$ (38,101)	$ (28,335)	$ (73,288)	$ (52,543)
Net loss per share attributable to ordinary shareholders - basic (in dollars per share)	$ (560)	$ (620)	$ (1,110)	$ (1,190)
Net loss per share attributable to ordinary shareholders - diluted (in dollars per share)	$ (560)	$ (620)	$ (1,110)	$ (1,190)
Weighted average ordinary shares outstanding - basic (in shares)	68,371,139	45,565,991	66,296,658	44,153,772
Weighted average ordinary shares outstanding - diluted (in shares)	68,371,139	45,565,991	66,296,658	44,153,772
Other comprehensive loss:
Foreign exchange translation adjustment	$ 81	$ 717	$ 45	$ 139
Other comprehensive loss:	$ (38,020)	$ (27,618)	$ (73,243)	$ (52,404)